BSH 2022 | Ongoing and future AML research at the Valk Lab
Peter Valk, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, discusses some upcoming research in the field of acute myeloid leukemia (AML) at the Valk Lab, drawing focus on the use of next-generation sequencing (NGS) to better identify mutations at diagnosis and improve risk-stratification of patients. Dr Valk also mentions his research which aims to use NGS to determine measurable residual disease (MRD). Following this, Dr Valk discusses previous research on the impact of various mutations on relapse rates in patients with AML, drawing focus on FLT3-ITD mutations. To conclude, Dr Valk discusses the benefits of using NGS, including the higher sensitivity of this method, and the importance of applying NGS-based approaches in future clinical trials. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
